Kymera Therapeutics, Inc. Appoints Vijay Sabesan as Senior Vice President, Technical Operations
December 06, 2021 at 08:00 am
Share
Kymera Therapeutics, Inc. announced the appointment of Vijay Sabesan as Senior Vice President, Technical Operations. Vijay Sabesan, Senior Vice President, Technical Operations: Vijay has extensive experience in process and pharmaceutical development, regulatory interactions, and manufacturing and has led CMC and Quality efforts towards commercial approval of VIBATIV® and YUPELRI®, and partnership deals with several large pharma companies. Prior to joining the company, he was Senior Vice President, Technical Operations at Theravance Biopharma where he was responsible for leading the process R&D, pharmaceutical development, analytical development, supply chain management and CMC project management functions.
Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodyâs own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platformâs capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.
KYMERA THERAPEUTICS, INC. 
